GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » 6-1 Month Momentum %

Nuvectis Pharma (Nuvectis Pharma) 6-1 Month Momentum % : -18.17% (As of May. 28, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-28), Nuvectis Pharma's 6-1 Month Momentum % is -18.17%.

The industry rank for Nuvectis Pharma's 6-1 Month Momentum % or its related term are showing as below:

NVCT's 6-1 Month Momentum % is ranked worse than
62.84% of 1526 companies
in the Biotechnology industry
Industry Median: -5.24 vs NVCT: -18.17

Competitive Comparison of Nuvectis Pharma's 6-1 Month Momentum %

For the Biotechnology subindustry, Nuvectis Pharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvectis Pharma's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's 6-1 Month Momentum % falls into.



Nuvectis Pharma  (NAS:NVCT) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvectis Pharma  (NAS:NVCT) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Nuvectis Pharma 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvectis Pharma (Nuvectis Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.
Executives
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024